
    <!DOCTYPE html>
    <html>
    <head>
        <style>
            body { 
                font-family: 'Segoe UI', Roboto, -apple-system, sans-serif; 
                max-width: 1200px; 
                margin: 0 auto; 
                padding: 20px; 
                background-color: #f0f2f5;
                line-height: 1.6;
            }
            .container { 
                background-color: white; 
                padding: 40px; 
                border-radius: 16px; 
                box-shadow: 0 4px 12px rgba(0,0,0,0.1);
            }
            .agent-section { 
                margin-bottom: 35px; 
                padding: 25px; 
                border-radius: 12px; 
                transition: all 0.3s ease;
            }
            .agent-section:hover {
                transform: translateY(-2px);
                box-shadow: 0 4px 15px rgba(0,0,0,0.1);
            }
            .final-annotation { 
                background-color: #f0f7ff; 
                border-left: 5px solid #2196f3; 
            }
            .validator { 
                background-color: #f0fdf4; 
                border-left: 5px solid #22c55e; 
            }
            .formatting { 
                background: linear-gradient(145deg, #fff7ed, #ffe4c4);
                border-left: 5px solid #f97316; 
                box-shadow: 0 4px 15px rgba(249, 115, 22, 0.1);
            }
            h2 { 
                color: #1a2b3c; 
                margin-top: 0; 
                font-size: 1.5rem;
                font-weight: 600;
                display: flex;
                align-items: center;
                gap: 10px;
            }
            ul { 
                margin: 15px 0; 
                padding-left: 20px; 
            }
            pre { 
                background-color: #f8fafc; 
                padding: 20px; 
                border-radius: 8px; 
                overflow-x: auto;
                font-family: 'Consolas', 'Monaco', monospace;
                font-size: 0.9rem;
                line-height: 1.5;
            }
            .validation-result { 
                font-weight: 600; 
                color: #16a34a; 
                padding: 12px 20px;
                background-color: #dcfce7; 
                border-radius: 8px; 
                display: inline-block;
                margin: 10px 0;
            }
            br { 
                margin-bottom: 8px; 
            }
            p {
                margin: 12px 0;
                color: #374151;
            }
            .summary-content {
                display: flex;
                flex-direction: column;
                gap: 24px;
            }
            .summary-item {
                display: flex;
                flex-direction: column;
                gap: 8px;
                background: rgba(255, 255, 255, 0.7);
                padding: 16px;
                border-radius: 12px;
                backdrop-filter: blur(8px);
                box-shadow: 0 2px 8px rgba(0, 0, 0, 0.05);
            }
            .summary-label {
                font-weight: 600;
                color: #c2410c;
                font-size: 0.95rem;
                text-transform: uppercase;
                letter-spacing: 0.5px;
            }
            .summary-value {
                color: #1f2937;
                font-size: 1.1rem;
                padding: 8px 16px;
                background-color: rgba(255, 255, 255, 0.9);
                border-radius: 8px;
                display: inline-block;
                box-shadow: 0 1px 3px rgba(0, 0, 0, 0.1);
            }
            .summary-list {
                margin: 0;
                padding-left: 24px;
                list-style-type: none;
            }
            .summary-list li {
                color: #1f2937;
                padding: 8px 0;
                position: relative;
            }
            .summary-list li:before {
                content: "‚Ä¢";
                color: #f97316;
                font-weight: bold;
                position: absolute;
                left: -20px;
            }
            .report-header {
                text-align: center;
                margin-bottom: 40px;
                padding-bottom: 30px;
                border-bottom: 2px solid rgba(249, 115, 22, 0.2);
            }
            
            .report-title {
                font-size: 2.5rem;
                font-weight: 800;
                color: #1a2b3c;
                margin: 0;
                padding: 0;
                background: linear-gradient(135deg, #f97316, #c2410c);
                -webkit-background-clip: text;
                -webkit-text-fill-color: transparent;
                letter-spacing: -0.5px;
            }
            
            .report-subtitle {
                font-size: 1.1rem;
                color: #64748b;
                margin-top: 8px;
                font-weight: 500;
            }
            .scoring { 
                background: linear-gradient(145deg, #f0fdf4, #dcfce7);
                border-left: 5px solid #22c55e;
                box-shadow: 0 4px 15px rgba(34, 197, 94, 0.1);
            }
            .scoring-content {
                display: flex;
                flex-direction: column;
                gap: 16px;
                color: #1f2937;
                line-height: 1.8;
            }
            .scoring-content br + br {
                content: "";
                display: block;
                margin: 12px 0;
            }
            .empty-list {
                color: #6b7280;
                font-style: italic;
            }
            .error-message {
                color: #dc2626;
                padding: 12px;
                background-color: #fef2f2;
                border-radius: 6px;
                border-left: 4px solid #dc2626;
            }
            .score-badge {
                background: linear-gradient(135deg, #22c55e, #16a34a);
                color: white;
                padding: 8px 16px;
                border-radius: 12px;
                font-size: 1.5rem;
                font-weight: 700;
                display: inline-block;
                margin: 12px 0;
                box-shadow: 0 4px 12px rgba(34, 197, 94, 0.2);
                position: relative;
                top: -10px;
            }
            .score-badge::before {
                content: "Score:";
                font-size: 0.9rem;
                font-weight: 500;
                margin-right: 8px;
                opacity: 0.9;
            }
        </style>
    </head>
    <body>
        <div class="container">
            <div class="report-header">
                <h1 class="report-title">CASSIA Analysis Report</h1>
                <p class="report-subtitle">Comprehensive Cell Type Analysis and Annotation</p>
            </div>
            
                <div class="agent-section final-annotation">
                    <h2>üîç Final Annotation Analysis</h2>
                    To annotate the cell type from the provided ranked marker list, I will follow the outlined steps:<br><br>### Step 1: List the Key Functional Markers<br>- **SLC5A8**: A sodium-coupled monocarboxylate transporter involved in the transport of short-chain fatty acids and other monocarboxylates.<br>- **G6PC3**: Encodes a glucose-6-phosphatase, involved in glucose metabolism.<br>- **ALDH2**: Aldehyde dehydrogenase involved in alcohol metabolism and detoxification.<br>- **ERBB2 (HER2)**: A receptor tyrosine kinase involved in cell growth and differentiation, often overexpressed in certain breast cancers.<br>- **RAC3**: A small GTPase involved in cell signaling and cytoskeletal organization.<br>- **CRABP2**: Cellular retinoic acid-binding protein, involved in retinoic acid signaling.<br><br>### Step 2: List the Key Cell Type Markers<br>- **CD24**: A cell surface protein often used as a marker for breast cancer stem cells and epithelial cells.<br>- **PODXL2**: Podocalyxin-like protein, associated with epithelial cells and involved in cell adhesion.<br>- **ERBB2 (HER2)**: Overexpressed in a subset of breast cancer cells, particularly HER2-positive breast cancer.<br>- **TFAP2A**: A transcription factor associated with epithelial cell differentiation and development.<br>- **RBP1**: Retinol-binding protein, associated with epithelial cells and involved in vitamin A metabolism.<br><br>### Step 3: Cross-reference Known Databases<br>Using databases such as the Human Protein Atlas, CellMarker, and literature on breast cancer, the following observations can be made:<br>- **CD24** and **ERBB2** are strongly associated with breast epithelial cells, particularly in the context of breast cancer.<br>- **TFAP2A** and **PODXL2** are markers for epithelial lineage, supporting the epithelial nature of the cells.<br>- **CRABP2** and **RBP1** are involved in retinoic acid signaling, which is relevant in epithelial cell differentiation.<br><br>### Step 4: Determine the Most Probable General Cell Type<br>Based on the expression of markers such as **CD24**, **ERBB2**, **TFAP2A**, and **PODXL2**, the most probable general cell type is **epithelial cells**, specifically those associated with breast tissue.<br><br>### Step 5: Identify the Top 3 Most Probable Sub Cell Types<br>1. **HER2-positive Breast Cancer Cells**: Due to the presence of **ERBB2** and **CD24**, which are indicative of HER2-positive breast cancer.<br>2. **Breast Cancer Stem Cells**: The presence of **CD24** and other markers like **ALDH2** suggests a stem-like phenotype.<br>3. **Luminal Epithelial Cells**: Markers such as **TFAP2A** and **RBP1** suggest a luminal epithelial origin.<br><br>The most likely subtype, based on the markers, is **HER2-positive Breast Cancer Cells** due to the strong presence of **ERBB2** and **CD24**.<br><br>### Step 6: Provide a Concise Summary of Your Analysis<br>The analysis of the ranked marker list from the breast cancer tissue dataset suggests that the cell cluster is most likely composed of epithelial cells, specifically HER2-positive breast cancer cells. This conclusion is supported by the high expression of markers such as **ERBB2** and **CD24**, which are characteristic of this subtype. Other markers like **TFAP2A** and **PODXL2** further support the epithelial nature of the cells.<br><br>FINAL ANNOTATION COMPLETED
                </div>
            
                <div class="agent-section validator">
                    <h2>‚úì Validation Check</h2>
                    <div class="validation-result">‚úÖ VALIDATION PASSED</div>
                    Validation result: VALIDATION PASSED<br><br>The proposed annotation result is consistent with the provided marker list and the identified cell type. Here's the breakdown:<br><br>1. **Marker Consistency**: <br>   - All the key functional markers and cell type markers mentioned in the annotation (SLC5A8, G6PC3, ALDH2, ERBB2, RAC3, CRABP2, CD24, PODXL2, TFAP2A, RBP1) are present in the provided marker list.<br>   - The markers used in the annotation are relevant to the identified cell type, which is epithelial cells, specifically HER2-positive breast cancer cells.<br><br>2. **Mixed Cell Type Consideration**:<br>   - The annotation considers the possibility of mixed cell types by identifying potential subtypes such as HER2-positive breast cancer cells, breast cancer stem cells, and luminal epithelial cells.<br>   - The presence of multiple markers like ERBB2, CD24, and ALDH2 supports the identification of HER2-positive breast cancer cells and breast cancer stem cells, respectively.<br><br>The annotation is well-supported by the marker list and the analysis provided, leading to a coherent and plausible identification of the cell type.
                </div>
            
                        <div class="agent-section formatting">
                            <h2>üìã Summary</h2>
                            
                        <div class="summary-content">
                            <div class="summary-item">
                                <span class="summary-label">Main Cell Type:</span>
                                <span class="summary-value">Epithelial Cells</span>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Sub Cell Types:</span>
                                <ul class="summary-list">
                                    <li>HER2-positive Breast Cancer Cells</li><li>Breast Cancer Stem Cells</li><li>Luminal Epithelial Cells</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Possible Mixed Cell Types:</span>
                                <ul class="summary-list">
                                    <li class="empty-list">No mixed cell types identified</li>
                                </ul>
                            </div>
                            
                            <div class="summary-item">
                                <span class="summary-label">Number of Markers:</span>
                                <span class="summary-value">50</span>
                            </div>
                        </div>
                    
                        </div>
                    
                    <div class="agent-section scoring">
                        <h2>üéØ Quality Assessment</h2>
                        <div class="score-badge">90</div>
                        <div class="scoring-content">
                            The annotation results provided demonstrate a strong understanding of the marker list and its relevance to the cell types associated with human breast cancer. The analysis correctly identifies key markers such as ERBB2 (HER2) and CD24, which are crucial for identifying HER2-positive breast cancer cells. This is a significant strength, as these markers are well-known indicators of this specific breast cancer subtype.<br><br>1. **Correctness of the Annotations**: The annotations are scientifically accurate. The identification of HER2-positive breast cancer cells as the primary subtype is well-supported by the presence of ERBB2 and CD24. Additionally, the consideration of breast cancer stem cells and luminal epithelial cells as potential subtypes is appropriate given the presence of markers like ALDH2 and TFAP2A.<br><br>2. **Balanced Consideration of Multiple Markers**: The analysis does a commendable job of considering a range of markers rather than over-focusing on a single one. The inclusion of functional markers such as SLC5A8 and G6PC3, alongside cell type markers like PODXL2 and RBP1, provides a well-rounded view of the cell population.<br><br>3. **Ability to Capture the General Picture**: The annotation captures the general picture of the cell populations effectively. It acknowledges the complexity of breast cancer cell types and the potential for mixed cell populations, which is a realistic representation of the biological scenario.<br><br>4. **Consideration of Marker Rank**: While the analysis does not explicitly discuss the rank of the markers, it does prioritize key markers like ERBB2 and CD24, which are crucial for the identification of HER2-positive breast cancer cells. This suggests an implicit understanding of the importance of marker rank.<br><br>5. **Potential Oversights**: One potential oversight is the lack of explicit discussion on the rank of markers, which could have strengthened the analysis. Additionally, while the annotation considers mixed cell types, it does not explore other possible subtypes that might be present, given the diversity of markers listed.<br><br>Overall, the annotation is thorough and well-reasoned, with a strong emphasis on key markers relevant to breast cancer. It provides a comprehensive view of the cell types present, with only minor areas for improvement.<br>
                        </div>
                    </div>
                
        </div>
    </body>
    </html>
    